$ZIOP News
Last published 4y ago
- 4y agoTCRTZIOPCARsgen Appoints Dr. Raffaele Baffa as Chief Medical OfficerPR NewswireSHANGHAI and BOSTON, April 7, 2022 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T cell therapies for the treatment of hematologic malignancies and solid tumors, announces that Dr. Raffa
- 4y agoZIOPZiopharm Oncology Highlights Operational Progress & Rebrands to Alaunos TherapeuticsGlobeNewswirePhase 1/2 TCR-T Library trial targeting KRAS, TP53 and EGFR mutations across six solid tumor indications is open for enrollment; continue to expect to dose the first patient in 1H 2022 Phase 1/2 IND amended to include four additional TCRs, bringing
- 4y agoZIOPPhase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumors - NCT05194735ClinicalTrials.govPhase I: To evaluate safety and tolerance of the cell transfer using common terminology criteria for adverse events (CTCAE v5.0), Phase II: To determine the objective response rate (ORR) (using RECIST v1.1 criteria) of subjects with solid cancers who receive autologous TCR-T cells, Phase II: To evaluate the safety and tolerance of the TCR-T cell infusion using standard CTCAE 5.0., (and 7 more...)
- 5y agoZIOPZiopharm Oncology Presents Preclinical Data Supporting TCR-T Library Approach at the Society for Immunotherapy of Cancer 2021 Annual MeetingGlobeNewswireHOUSTON, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. ("Ziopharm" or the "Company") (NASDAQ:ZIOP), today announced the presentation of preclinical data highlighting the potential of neoantigen-specific TCR-T cells for the treatment of soli
- 5y agoZIOPZiopharm Oncology Reports Third Quarter 2021 Financial Results and Provides Business UpdateGlobeNewswireHOUSTON, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. ("Ziopharm" or the "Company") (NASDAQ:ZIOP), today announced financial results for the third quarter ended September 30, 2021 and provided a business update. "I am impres
- 5y agoZIOPZiopharm Oncology to Report Third Quarter Financial Results on November 8, 2021GlobeNewswireHOUSTON, Nov. 01, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. ("Ziopharm" or the "Company") (NASDAQ:ZIOP), today announced that it will report financial results for the third quarter ended September 30, 2021 on Monday, November 8, 2021, after the
- 5y agoACERFLUXNTRBOCGN+1Thinking about buying stock in Acer Therapeutics, Ziopharm Oncology, Nutriband, Ocugen, or Flux Power?PR NewswireNEW YORK, Oct. 6, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ACER, ZIOP, NTRB, OCGN, and FLUX. T
- 5y agoAGFYNINEOCGNRSI+1Thinking about buying stock in Agrify, Rush Street Interactive, Ocugen, Nine Energy Service, or Ziopharm Oncology?PR NewswireNEW YORK, Oct. 5, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AGFY, RSI, OCGN, NINE, and ZIOP. To
- 5y agoZIOPZiopharm Oncology Announces Strategic Reduction in Workforce and Extension in Cash RunwayGlobeNewswire• Over 50% reduction in personnel • Cost reductions expected to extend the cash runway into the first half of 2023 • The first patient in its TCR-T Library Phase I/II clinical trial is expected to be dosed in 1H2022 BOSTON and HOUSTON, Sep
- 5y agoABCLADAPGLYCQURE+1Thinking about buying stock in Adaptimmune Therapeutics, Ziopharm Oncology, Uniqure NV, GlycoMimetics, or AbCellera Biologics?PR NewswireNEW YORK, Sept. 7, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ADAP, ZIOP, QURE, GLYC, and ABCL.
- 5y agoZIOPZiopharm Oncology to Participate in September Investor ConferencesGlobeNewswireBOSTON and HOUSTON, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. ("Ziopharm" or the "Company") (NASDAQ:ZIOP), today announced that Kevin S. Boyle, Sr., Chief Executive Officer of Ziopharm, is scheduled to participate in five upcoming virt
- 5y agoZIOPZiopharm Oncology Appoints Kevin S. Boyle, Sr., as Chief Executive Officer and Announces other Executive PromotionsGlobeNewswireMr. Boyle brings over 20 years of executive business leadership in CEO, CFO and operational leadership roles Strong track record of successfully guiding companies and creating shareholder value through disciplined capital management and achievement of
- 5y agoZIOPZiopharm Oncology Provides Second Quarter 2021 Corporate UpdatesGlobeNewswireAccomplished key milestones in groundbreaking TCR-T Library program, including commissioning of Company's manufacturing facility and presentation of favorable preclinical data Closed venture debt financing with Silicon Valley Bank, strengthening balan
- 5y agoZIOPZIOPHARM Oncology Inc (ZIOP) Q2 2021 Earnings Call TranscriptEarnings Call TranscriptsZIOP earnings call for the period ending June 30, 2021.
- 5y agoZIOPZiopharm Oncology to Report Second Quarter Financial Results on August 9, 2021GlobeNewswireBOSTON, July 26, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (NASDAQ:ZIOP), today announced that management will host a conference call and webcast on Monday, August 9, at 4:30 p.m. EDT to provide a corporate update and discuss financial results f
- 5y agoZIOPZiopharm Oncology to Participate in Upcoming ConferencesGlobeNewswireBOSTON, May 24, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. ("Ziopharm" or the "Company") (NASDAQ:ZIOP), a clinical-stage cellular therapy company focused on hematologic and solid tumor cancers, today announced that Company management will partici
- 5y agoZIOPZiopharm Oncology Reinforces Clear and Bold Vision for Delivering Value at Annual Shareholders MeetingGlobeNewswire– Highlighted distinctive cellular therapy program, market opportunity and value proposition – Shared optimistic outlook and commitment to deliver value to shareholders – Encouraged by overwhelming vote of shareholders in favor of the Compan
- 5y agoZIOPZiopharm Oncology Reports First Quarter 2021 Financial Results and Provides Corporate UpdatesGlobeNewswire– Annual shareholder meeting planned for May 19, 2021 – Company to host conference call today at 4:30 pm ET BOSTON, May 06, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. ("Ziopharm" or the "Company") (NASDAQ:ZIOP), today announced its fin
- 5y agoZIOPZIOPHARM Oncology, Inc. to Host Earnings CallACCESS NewswireNEW YORK, NY / ACCESSWIRE / May 6, 2021 / ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) will be discussing their earnings results in their 2021 First Quarter Earnings call to be held on May 6, 2021 at 4:30 PM Eastern Time. To listen to the event live or access
- 5y agoZIOPZiopharm Oncology Inc (ZIOP) Q1 2021 Earnings Call TranscriptEarnings Call TranscriptsZIOP earnings call for the period ending March 31, 2021.
- 5y agoZIOPZiopharm Oncology Scientific Advisor Laurence Cooper, MD, PhD, to Present at University of Pennsylvania Cellicon Valley '21 Two-Day Live Virtual Educational SymposiumGlobeNewswireBOSTON, May 04, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. ("Ziopharm" or the "Company") (NASDAQ:ZIOP), announced today that Laurence J.N. Cooper, PhD, MD, Scientific Advisor to the Company, will present and participate in an upcoming panel discu
- 5y agoZIOPZiopharm Oncology to Report First Quarter Financial Results on May 6, 2021GlobeNewswireBOSTON, April 29, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (NASDAQ:ZIOP), today announced it will report first quarter 2021 financial results on Thursday, May 6, 2021 after the financial markets close, and host its annual shareholder meeting on
- 5y agoZIOPZiopharm Oncology Scientific Advisor Laurence J. N. Cooper, PhD, MD, Presented Today at Aldevron's Virtual Breakthrough Speakers SeriesGlobeNewswireBOSTON, April 28, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. ("Ziopharm" or the "Company") (NASDAQ:ZIOP), announced today that Laurence J.N. Cooper, PhD, MD, Scientific Advisor to the Company, was the inaugural presenter at Aldevron's Virtual Bre
- 5y agoZIOPZiopharm Oncology Announces First Patient Infused in CD19 RPM CAR-T Phase I Clinical Trial Being Conducted by Joint Venture Partner Eden BioCellGlobeNewswireBOSTON and HOUSTON and TAIPEI, Taiwan, April 19, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. ("Ziopharm" or the "Company") (NASDAQ:ZIOP), announced today that in March, the first patient was infused in the CD19-Specific Rapid Personalized Manufact
- 5y agoZIOPZiopharm Oncology to Present Poster at American Association for Cancer Research Virtual 2021 Annual MeetingGlobeNewswireBOSTON and HOUSTON, April 07, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (“Ziopharm” or the “Company”) (Nasdaq: ZIOP), announced today it will be presenting a poster at the upcoming American...
- 5y agoZIOPZiopharm Oncology Inc (ZIOP) Q4 2020 Earnings Call TranscriptEarnings Call TranscriptsZIOP earnings call for the period ending December 31, 2020.
- 5y agoZIOPZiopharm Oncology Provides Leadership and Corporate Updates; Reports Fourth Quarter and Full Year 2020 Financial ResultsGlobeNewswireHeidi Hagen Appointed Interim Chief Executive Officer Replacing Dr. Laurence Cooper; Search for Permanent CEO Initiated Dr. Laurence Cooper Expected to Continue with Company in a Scientific Advisory...
- 5y agoZIOPEVFMONTXNKTRIncreasing R&D Studies to Develop Cancer Vaccines Attributed to Spike in Number of Cancer PatientsPR NewswireOvarian cancer and its rising incidence rate is a growing concern worldwide and the rising incidence of ovarian cancer will be driving the ovarian...
- 5y agoZIOPZiopharm Oncology to Report Fourth Quarter and Full Year 2020 Financial Results and Host Webcast on February 25, 2021GlobeNewswireBOSTON, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (the “Company”) (Nasdaq: ZIOP), today announced the Company will host a conference call and webcast to discuss financial results for...
- 5y agoZIOPZiopharm Oncology Announces Election of Robert Postma to its Board of DirectorsGlobeNewswireBOSTON, Feb. 05, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (“Ziopharm” or “the Company”) (Nasdaq:ZIOP) today announced the election of Robert Postma to its Board of Directors (the “Board”),...
- 5y agoZIOPZiopharm Oncology Announces Election of James Huang as Chairman of the Board of DirectorsGlobeNewswire– Mr. Huang is a veteran industry entrepreneur with 20+ years founding and funding biotech innovation – – Heidi Hagen elected Lead Independent Director – BOSTON, Jan. 14, 2021 (GLOBE NEWSWIRE) --...
- 5y agoZIOPZiopharm to Participate in Upcoming January ConferencesGlobeNewswireBOSTON, Dec. 23, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (“Ziopharm” or “the Company”) (Nasdaq: ZIOP), today announced that Laurence Cooper, M.D., Ph.D., Chief Executive Officer of...
- 5y agoZIOPZiopharm Oncology Announces Clearance of Taiwan’s First IND of Non-viral CAR-T for the Treatment of Relapsed CD19+ Leukemias and LymphomasGlobeNewswire– Advances Eden BioCell’s clinical program to validate Rapid Personalized Manufacturing (RPM) – – Clinical trial to study autologous CD19-specific CAR-T using RPM technology designed to reduce cost...
- 5y agoZIOPWaterMill Asset Management Issues Statement Regarding Consent Solicitation at Ziopharm OncologyBusiness WireNEW YORK--(BUSINESS WIRE)--WaterMill Asset Management Corp. (together with its affiliates, “WaterMill” or “we”), a sizable and long-term shareholder of Ziopharm Oncology, Inc. (NASDAQ: ZIOP) (“Ziopharm” or the “Company”), today announced that it received the requisite number of written consents to add all three of its director candidates – Robert Postma, Jaime Vieser and Holger Weis – to the Compa ...
- 5y agoZIOPZiopharm Comments on Consent Solicitation ResultsGlobeNewswireBOSTON, Dec. 16, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (Nasdaq: ZIOP) (“Ziopharm” or the “Company”), today issued a statement in connection with the consent solicitation (the “Consent...
- 5y agoZIOPZiopharm Oncology Announces Chief Financial Officer to Step DownGlobeNewswireBOSTON, Dec. 14, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (Nasdaq: ZIOP) (“Ziopharm” or the “Company”), today announced that Satyavrat “Sath” Shukla, CFA, Chief Financial Officer, has...
- 5y agoZIOPWaterMill Asset Management Addresses Ziopharm Oncology’s Latest Distortion and Recent ThreatBusiness WireNEW YORK--(BUSINESS WIRE)--WaterMill Asset Management Corp. (together with its affiliates, “WaterMill” or “we”) today responded to the latest element of the low-road campaign that Ziopharm Oncology, Inc. (NASDAQ: ZIOP) (“Ziopharm” or the “Company”) is waging in response to our consent solicitation.
- 5y agoZIOPZiopharm Comments on Delay of WaterMill’s Stated Consent DeadlineGlobeNewswireZiopharm Recommends Shareholders Return the GREEN Consent Revocation Card BOSTON, Dec. 11, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (Nasdaq: ZIOP) (“Ziopharm” or the “Company”), today...
- 5y agoZIOPEgan-Jones Recommends Against Electing Dissident’s Full Slate of Nominees to Ziopharm BoardGlobeNewswireRecommends Against Electing WaterMill Nominee Jaime Vieser Ziopharm Continues to Recommend that Shareholders Support Company’s Strong Progress by Returning the GREEN Consent Revocation Card ...
- 5y agoZIOPBNTCFIXXTLOGWaterMill Asset Management Reinforces the Need for Meaningful and Urgent Change at Ziopharm OncologyBusiness WireNEW YORK--(BUSINESS WIRE)--WaterMill Asset Management Corp. (together with its affiliates, “WaterMill” or “we”), which collectively with the other participants in its consent solicitation beneficially owns approximately 3.3% of the outstanding shares of Ziopharm Oncology, Inc. (NASDAQ: ZIOP) (“Ziopharm” or the “Company”), today issued the below letter to shareholders.
- 5y agoZIOPZiopharm Details Actions in Response to Shareholder FeedbackGlobeNewswireHas Held Several Discussions with WaterMill to Reach an Amicable Resolution to Consent Solicitation Board Accepts Resignation of Director Elan Ezickson Reiterates...
- 5y agoZIOPGlass Lewis Recommends Ziopharm Shareholders Vote on the WHITE Consent Card for All of WaterMill’s Director Candidates and ProposalsBusiness WireNEW YORK--(BUSINESS WIRE)--WaterMill Asset Management Corp. (together with its affiliates, “WaterMill” or “we”) today announced that Glass, Lewis & Co., LLC (“Glass Lewis”), a leading proxy advisory firm, has endorsed its case for meaningful change at Ziopharm Oncology, Inc. (NASDAQ: ZIOP) (“Ziopharm” or the “Company”) and recommended shareholders vote for all five proposals on WaterMill’s WHITE c ...
- 5y agoZIOPWaterMill Asset Management Refutes Ziopharm Oncology’s Desperate, Low-Road Smear CampaignBusiness WireNEW YORK--(BUSINESS WIRE)--WaterMill Asset Management Corp. (together with its affiliates, “WaterMill” or “we”), which collectively with the other participants in its consent solicitation beneficially owns approximately 3.3% of the outstanding shares of Ziopharm Oncology, Inc. (NASDAQ: ZIOP) (“Ziopharm” or the “Company”), today responded to the low-road campaign that the incumbent Board of Directo ...
- 5y agoZIOPZiopharm Comments on Institutional Shareholder Services’ Recommendation to Reject WaterMill’s Attempt to Remove Half of Ziopharm’s Board of DirectorsGlobeNewswireISS Acknowledges Ziopharm’s Outperformance of its Peer Group During Chairman Scott Tarriff’s Tenure Court Filings Raise Concerns About Professional Past of WaterMill Nominee Holger Weis Ziopharm...
- 5y agoZIOPISS Recommends Ziopharm Shareholders Vote for Change on WaterMill Asset Management’s WHITE Consent CardBusiness WireNEW YORK--(BUSINESS WIRE)--WaterMill Asset Management Corp. (together with its affiliates, “WaterMill” or “we”), which collectively with the other participants in its consent solicitation beneficially owns approximately 3.3% of the outstanding shares of Ziopharm Oncology, Inc. (NASDAQ: ZIOP) (“Ziopharm” or the “Company”), today announced that Institutional Shareholder Services Inc. (“ISS”), a lead ...
- 5y agoZIOPWaterMill Asset Management Sets the Record Straight Following Ziopharm’s Apparent Attempt to Mislead Shareholders and Rewrite HistoryBusiness WireNEW YORK--(BUSINESS WIRE)--WaterMill Asset Management Corp. (together with its affiliates, “WaterMill” or “we”), which collectively with the other participants in its consent solicitation beneficially owns approximately 3.3% of the outstanding shares of Ziopharm Oncology, Inc. (NASDAQ: ZIOP) (“Ziopharm” or the “Company”), today released a new rebuttal presentation in response to the incumbent Boar ...
- 5y agoZIOPZiopharm Releases Investor Presentation Highlighting Execution of Strategy and Substantial Board Refreshment to Enhance Shareholder ValueGlobeNewswireContinues to Execute on Strategy to Ensure Strong Long-Term Outlook Outlines Additions of Five Highly Qualified Industry Veterans to Board Over the Last 18 Months BOSTON, Nov. 20, 2020 (GLOBE...
- 5y agoZIOPWaterMill Asset Management Releases Presentation Detailing the Case for Urgent Change Atop Ziopharm OncologyBusiness WireNEW YORK--(BUSINESS WIRE)--WaterMill Asset Management Corp. (together with its affiliates, “WaterMill” or “we”), which collectively with the other participants in its consent solicitation beneficially owns approximately 3.3% of the outstanding shares of Ziopharm Oncology, Inc. (NASDAQ: ZIOP) (“Ziopharm” or the “Company”), today released a 55-page presentation that details the case for urgent chang ...
- 5y agoZIOPZiopharm Oncology Presents Encouraging Clinical Data for Controlled IL-12 for the Treatment of Glioblastoma and DIPG at the 2020 Society for Neuro-Oncology Annual MeetingGlobeNewswire– First Data from Ongoing Phase 2 Study of Controlled IL-12 in Combination with Cemiplimab Demonstrate Promising Safety Profile in rGBM, and a Confirmed Partial Response – – Updated Interim Data...
- 5y agoZIOPWhite Rock Capital Supports WaterMill's Case for Change at Ziopharm OncologyPR NewswireWhite Rock Capital Partners, L.P. ("White Rock Capital"), along with all of its related entities, will vote 100% of its approximately 6.1 million...